Business, New York Academy of Medicine, Regional Events, Surgery and Neurotechnology

Tom Oxley to Keynote the 2024 Bioelectronic Medicine Forum in New York City

NEW YORK, N.Y. -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Seventh Annual Bioelectronic Medicine Forum will take place on April 5, 2024. The one-day event will be held at the New York Academy of Medicine in Manhattan.

The keynote speaker at this year's event is Tom Oxley, CEO of Synchron and an interventional neurologist at Mount Sinai Health System. Synchron's internationally acclaimed stentrode device can record brain activity from within a blood vessel. In the intended application of the technology, the user's thoughts are captured, decoded and passed wirelessly through the skin to enable control of digital devices that enable movement and speech restoration to previously paralyzed patients.

Executives and entrepreneurs from several early stage and startup bioelectronic medicine firms will make presentations at the conference. Among these are Sinaptica Therapeutics, Neurosoft Bioelectronics, Helius Medical, PathMaker Neurosystems, Five Liters, Nia Therapeutics, Backstop Neural, WISE srl, and NeuroSigma.

There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate sessions at the event. A panel on investment will feature Diana Saraceni, General Partner at Panakes Partners, David Neustaedter, Venture Partner at Deerfield, and others.

Cirtec Medical is the Platinum Sponsor of the conference. MCRA is the Silver Sponsor and CorTec is the Bronze Sponsor.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This seventh-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry."

For more information on the 2024 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

RELATED LINKS:
https://www.synchron.com/
https://cirtecmed.com/
https://www.mcra.com/
https://www.cortec-neuro.com/

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Divergent CRO, Drugs and Pharmaceuticals, Product Launches

Divergent CRO Announces Launch of New Contract Research Organization

ATLANTA, Ga. -- Divergent CRO, a leading provider of clinical services to biotech and device companies, is pleased to announce the official launch of its new Contract Research Organization (CRO). This new venture aims to revolutionize the research and development process by offering comprehensive and tailored clinical services to meet the unique needs of the biotech and device industries.

With an unwavering commitment to excellence, Divergent CRO provides a wide range of services, including clinical trial management, regulatory affairs, data management, biostatistics, and medical writing. By leveraging our extensive expertise, we are dedicated to helping our clients accelerate the development of innovative biopharmaceuticals and medical devices.

Our team of highly skilled professionals, including experienced clinical researchers, project managers, and regulatory specialists, is dedicated to delivering the highest standards of quality and efficiency throughout each stage of the clinical trial process. We understand the challenges faced by biotech and device companies and are committed to providing flexible and cost-effective solutions to meet their specific needs.

Divergent CRO is equipped with cutting-edge technology and infrastructure to ensure the smooth execution of clinical trials. Our advanced data management systems and secure facilities ensure the confidentiality and integrity of study data, while our robust quality assurance processes guarantee compliance with regulatory requirements.

"We are thrilled to launch our new Contract Research Organization and partner with biotech and device companies to advance the development of life-changing therapies," said Divergent CRO's Owner-Partners. "Our team is dedicated to delivering exceptional results and providing the highest level of service to our clients. With our expertise and commitment to excellence, we are confident that we can make a significant impact on the success of their clinical programs."

Divergent CRO is now accepting inquiries and is available to discuss collaboration opportunities with biotech and device companies seeking to enhance their clinical research capabilities.

For more information, please visit Divergentcro.com or contact our business development team at Customerservice@divergentcro.com or (888) 342-1447.

About Divergent CRO:

Divergent CRO is a leading provider of clinical services to biotech and device companies. With a focus on innovation and quality, we strive to accelerate the development of life-changing therapies through our comprehensive and tailored clinical services. We thrive on leaving our clients and patients satisfied by improving human health and wellness. Our team of experts is dedicated to delivering exceptional results and providing the highest level of service to our clients. At Divergent CRO, we don't just manage clinical trials; we craft personalized solutions, striving to be the difference by transforming challenges into triumphs in the pursuit of groundbreaking healthcare innovation.

Learn more at: https://divergentcro.com/

Social Links:

LinkedIn Page: https://www.linkedin.com/company/divergentcro/

Instagram: https://www.instagram.com/divergent.cro/

TikTok: https://www.tiktok.com/@divergentcro1

YouTube: https://www.youtube.com/@DivergentCRO

Featured Podcasts:

The Jali Podcast - Melyssa Barrett/DivergentCRO - https://melyssabarrett.com/the-jali-podcast/

Episode Thirty-one - AMY HUTTO, PRODUCTIVITY COACH - https://amyhutto.com/podcast/s1ep30

Related link: https://divergentcro.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, NonProfit and Charities

BioAustinCTX Adds Cindy WalkerPeach and Ryan Hawkins to the Board of Directors

AUSTIN, Texas -- BioAustinCTX, Central Texas' Life Science industry organization, announced today the appointment of Cindy WalkerPeach, PhD and Ryan Hawkins to its Board of Directors.

Cindy WalkerPeach has been involved in the Central Texas life science ecosystem since 1996, having relocated to Austin to join a bioscience startup. She currently leads the development of the Nexxus Project at the University of Texas at Austin and serves on the national faculty for the National Institutes of Health (NIH) and National Science Foundation (NSF) Innovation Corps (I-Corps) Programs. Prior to UT, she was the Chief Product Development Officer at the Cancer Prevention & Research Institute of Texas (CPRIT). Prior to government service, Dr. WalkerPeach has 20+ years experience in the biotechnology sector as a member of several life science company management teams, all located in Central Texas, where she led product development and commercial operations.

"It's an exciting time, as Central Texas continues its development into a first-class life sciences hub. BioAustinCTX has been, and continues to be, a critical component for connectivity within the region," said WalkerPeach.

Ryan Hawkins is an accomplished biopharmaceutical leader with 25 years' experience in the life sciences. Ryan serves as the Chief Operating Officer at Disruption Labs, a plant-derived delivery technology company serving the nutraceutical industry. Prior to joining Disruption Labs, Ryan was responsible for Technical Operations at Molecular Templates, a clinical stage biotechnology company and spent 20 years in the biopharmaceutical contract development and manufacturing industry.

"All of the ingredients are present in Austin and Central Texas to have thriving, dynamic life science community that creates benefits beyond the advertised value proposition. Being a part of creating our secret sauce recipe that attracts people, conversation, companies, and community building is very exciting. As a member of the BioAustinCTX board, I look forward to unlocking our community's potential in this regard," said Hawkins.

"Cindy and Ryan bring tremendous experience and knowledge and we look forward to the energy and expertise they will bring to advancing BioAustinCTX's pivotal role in growing the life science ecosystem in Central Texas," said Scott Collins, Board of Directors President.

About BioAustinCTX:

BioAustinCTX is a nonprofit organization based in Austin, Texas focused on advancing the life science industry in the Central Texas Region. Visit BioAustinCTX for more information: https://bioaustinctx.com/.

Related link: https://bioaustinctx.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Regional Events, Surgery and Neurotechnology

Emerging Neurotechnology Startups to Present at 2023 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that several promising neurotechnology startups and early-stage firms will present at the 2023 Neurotech Leaders Forum in San Francisco, November 6-7. The 23rd annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Among the new and emerging neurotech firms presenting at the conference are Opto Biosystems, a U.K. developer of novel diagnostics for brain cancer, NeuraLace Medical, a San Diego-based manufacturer of noninvasive therapies for treating chronic pain, Spark Biomedical, a Texas firm developing noninvasive therapies for treating addiction, and Harmonic Pain Solutions, an Atlanta, GA-area developer of wearable pain devices that use mechanical stimulation.

Jim Schuermann, president and CEO of Saluda Medical, will deliver the keynote address on the morning of November 6. He will speak on the topic "New Directions in Neuromodulation."

Daniel Kraft, founder of NextMed Health, chair of medicine for Singularity University, and chair of the XPrize Pandemic & Health Alliance, will deliver a keynote address on November 7 devoted to the topic, "The Future of Health and Medicine: Where Can Technology Take Us?" Kraft is board certified in internal medicine and pediatrics and completed fellowships in hematology/oncology and bone marrow transplantation at Stanford. He has given six TED & TEDMED talks.

Another featured presenter will be Prasad Shirvalkar, an associate professor at UC San Francisco School of Medicine, who recently co-authored a seminal paper relating to pain biomarkers. Chris Rozell, a professor at Georgia Tech, who recently coauthored a paper on biomarkers for depression, will also make a presentation at the event.

Neurotech Reports senior contributing editor JoJo Platt will moderate a panel titled "Neurotech Investment: Bouncing Back from the Downturn," which will feature advice and recommendations from several venture capital professionals, including Sara Shnider from Joy Ventures, Martin Dieck from Neurotechnology Investors, and Suraj Mudichintala from Action Potential Venture Capital.

Neurotech Reports senior consulting editor Jeremy Koff will moderate a session titled "Changing Landscape: New SCS and PNS Vendors Enter the Scene," which will examine the current competitive environment in neuromodulation. Neurotech Reports editor James Cavuoto will moderate a session titled "Interpreting the Data: Neuromodulation Vendors Ward Off Negative Publications. And Neurotech Reports contributing editor Victor Pikov will moderate a session titled "Choosing Our Role Models: What Neurotech Can Learn from Other Healthcare Industries."

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Valtronic, Velentium, Focus, Neo-Bionica, and Iris Biomedical are Silver Sponsors, while TTP and Microdul are Bronze sponsors.

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/leadersforum.html

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles

Neo-Bionica Appoints Uli Gommel As Chief Technology Officer

LOS ANGELES, Calif. -- Neo-Bionica, a leading innovator in the field of medical device development and manufacturing, is thrilled to announce the appointment of Uli Gommel as its new Chief Technology Officer (CTO). Uli will lead Neo-Bionica's technology division spearheading its mission to revolutionize the way that companies bring novel neurotechnologies and smart MedTech devices to market.

Uli Gommel joins Neo-Bionica as a global leader in medical engineering with two decades experience spanning Europe, Asia and the US. Prior to joining Neo-Bionica, he was the Director of Mechanical Engineering at Advanced Bionics. There he led the end-to-end development and launch of the HiResTM Ultra 3D Cochelar Implant, a groundbreaking device which won the MedTech Breakthrough Award in 2019 for best overall medical device solution. Uli's expertise also extends to the development of pediatric cochlear implants, specialized surgical tools and high-resolution implantable electrode arrays.

Based in the US and with a proven track record in growing global MedTech teams, Uli's appointment demonstrates Neo-Bionica's commitment to growing its US presence. As CTO of Neo-Bionica, Uli will oversee design, development, and manufacturing services, providing expert insights for clients developing next-generation neurotech and smart MedTech devices. Through an outstanding depth and breadth of bioengineering expertise, fabrication skills, and regulatory know-how, Uli's experience will help to accelerate the development of implantable and wearable neurotechnologies and bioelectronics devices.

"Neo-Bionica is pushing the boundaries of what is possible in the field of neurotechnology," said Uli. "I am honored to join this talented team and contribute to our shared vision of enhancing the lives of the people who will benefit from these products."

Neo-Bionica's CEO, Dr. Ludovic Labat, said "Not only does Uli's expertise and vision align perfectly with our mission to help companies realize the promise of bioelectric devices, but his presence in the US also signals our commitment to serving the needs of this significant market. With his leadership, Neo-Bionica will continue to grow quickly and smartly."

Uli will be leading a team of highly experienced industry and academic professionals with backgrounds in MedTech, mechanical and electronic engineering and previous experience from top-tier institutions including Invetech, Medtronic, Cochlear, Bionics Institute and Planet Innovation.

Neo-Bionica was established in 2021 to meet a need in the Australian market. Despite Australia's deep expertise in the development of advanced MedTech and Neurotech devices, emerging Australian Neurotech innovators were frequently forced to go overseas to prototype and manufacture their devices. Neo-Bionica was established to meet this gap in the market and since its establishment, its expertise and services have been in high demand from not only local innovators but international clients. Given this demand, Neo-Bionica fast-tracked its plan to establish a permanent foothold in the US with Uli's appointment.

About Neo-Bionica:

Neo-Bionica is an advanced Medtech manufacturer that specializes in providing commercialization and manufacturing services to develop digitally-enabled bionic and smart, neurotech medical device innovations. Neo-Bionica's expertise includes developing AI-powered devices designed to restore human function and smart sensors capable of intelligently monitoring human physiology.

Headquartered in Melbourne, Australia, Neo-Bionica has quickly gained recognition within the industry. Neo-Bionica is proud to be empowering the next generation of MedTech innovators with advanced manufacturing services. https://neo-bionica.com/

Related link: https://neo-bionica.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Free News Articles, Sciences

Award-winning universal vaccine method calls for deeper scientific exploration – The Slammer Method

CHESAPEAKE, Va. -- A new universal vaccine method developed by Eric Kikkert is outlined in an article he wrote called: "The Slammer Method: How to create effective vaccines." It recently appeared in the "Journal of Infectious Diseases and Therapy" and is proposed to work in not just humans, but animals too. The material was presented at the 2023 12th International Conference for Tropical Medicine and Infectious Disease in London, received an award and established as a universal method to create effective vaccines.

As the name denotes, The Slammer Method, quite literally places the organism into "The Slammer" and crushes it through powerful force. The method entails using a series of approaches to dismantle the organism and prepare it for the body's immune system.

It's a new and inspirational method which uses the concepts of physics, biologics and natural extremes to combat an ever-changing environment of infectious diseases.

While the method is rudimentary in design, it's through its simplicity that great things are achievable. It all starts with a container that's capable of withstanding vast amounts of pressure and then subjecting an organism to multiple tests. In turn, these tests will determine how to proceed should the organism cease to function with pressure alone. After that, the next steps can happen which include adding the chemical equivalent of the enzyme or MPO used by the white blood cell to break down the organism.

Medical research will be able to verify that the organism is unable to feed or reproduce and The Slammer Method can be used for all infectious diseases, including HIV. It's derived from several factors in nature and has untapped possibilities.

"The potential to save countless lives is very real," Kikkert says. "It should be seriously explored through modern science, medical research and technological engineering."

Read the complete article: https://www.hilarispublisher.com/open-access/how-to-create-effective-vaccines-93437.html

View the transcript of the presentation in London: https://www.allforyou2020.org/post/how-to-create-effective-vaccines

About Eric Kikkert:

Eric Kikkert has expertise in mechanical engineering and physics. He has a deep understanding of quantum relativity, quantum structures and mechanics and has produced advanced mathematical methods and concepts to create new formulas which permit unification of physics and relativity. It's here that he commits his understandings to biology to reverse engineer the quantum structure with particle physics.

MEDIA CONTACT:
Eric Kikkert, +1-757-949-8864, email: KikkertEric[at]icloud.com

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Free News Articles, Surgery and Neurotechnology

Helen Mayberg to Keynote 2023 Bioelectronic Medicine Forum in New York City

NEW YORK, N.Y. -- Neurotech Reports, the publisher of the Neurotech Business Report and BioElectRx Business Report newsletters, announced that the Sixth Annual Bioelectronic Medicine Forum will take place on April 4, 2023. The one-day event will be held at the New York Academy of Medicine in Manhattan.

The keynote speaker at this year's event is Helen Mayberg, Director of the Nash Family Center for Advanced Circuit Therapeutics at Mount Sinai School of Medicine. Mayberg is recognized as one of the pioneers of neuromodulation for treating psychiatric disorders. She will speak on the topic, "Pharmacological therapies simply aren't enough."

Other sessions will cover a range of technologies and indications for bioelectronic medicine, including applications in cardiovascular medicine, inflammation, gastrointestinal disorders, and many other clinical specialties. There will also be several informative panel discussions on key topics such as investment, emerging technologies, and reimbursement. Neurotech Reports editors James Cavuoto, Jeremy Koff, JoJo Platt, and Victor Pikov will moderate sessions at the event

The founders and CEOs of several promising bioelectronic medicine startups will also present at the conference. Entrepreneur presenters Brad Schmidt, CEO of Panaxium, which is developing a new "iontronic" brain interface, Marc Powell, CEO of Reach Neuro, which has developed a new stroke rehabilitation therapy, Luca Ravagnan, CEO of WISE srl, an Italian firm developing thin, stretchable brain electrodes, and Karen Crow, CEO of NeuroGeneces, which has developed a sleepband that performs brain health assessment using A.I. and EEG data.

Cirtec Medical is the Platinum Sponsor of the conference. MST is the Gold Sponsor and Valtronic and Velentium are Silver Sponsors.

"Bioelectronic medicine is one of the most promising new segments of the healthcare industry," said James Cavuoto, editor and publisher at Neurotech Reports. "This sixth-annual conference will be a key meeting place for entrepreneurs and executives helping to build this industry."

For more information on the 2023 Bioelectronic Medicine Forum, contact Neurotech Reports at 415 546 1259 or visit this link: https://neurotechreports.com/pages/bioelectronic-medicine-forum.html.

Related link: https://www.neurotechreports.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Business, Education and Schools, Free News Articles, Product Launches, Sciences

The BioBuilder Educational Foundation Initiates Plan to Train Bioeconomy Workforce

NEWTON, Mass. -- The BioBuilder Educational Foundation, Inc. ("BioBuilder"), which has a decade of empowering teachers and schools to bring synthetic biology education to school districts in 47 states, today announced its launch of a strategic planning process designed to grow the bioeconomy workforce at scale in urban, rural, and tribal communities.

This effort represents an expansion of the work BioBuilder has accomplished to date in Eastern Tennessee. BioBuilder spent several years partnering with secondary schools and East Tennessee State University (ETSU). Last year, the University produced a Synthetic Biology Task Force Report that recommended a roadmap to raise awareness of career opportunities available via synthetic biology and the bioeconomy, and to create programs at the University to teach students and ready them for those jobs.

BioBuilder's next phase, in which it will build on the learning from Eastern Tennessee, is to develop a plan to grow the bioeconomy workforce across the USA, while still considering local contexts. The work will be made possible by support from Schmidt Futures, a philanthropic initiative of Eric and Wendy Schmidt that bets early on exceptional people making the world better.

Dr. Natalie Kuldell, founder and Executive Director of BioBuilder, shared, "BioBuilder is committed to inspiring students to learn and love life science, on a path to bright futures, successful careers, and a better world. We're thankful for Schmidt Futures support of our next steps, as we address the bioeconomy's shortage of trained technical talent."

Schmidt Futures is a philanthropic initiative founded by Eric and Wendy Schmidt that bets early on exceptional people making the world better. Through work with partners like BioBuilder, Schmidt Futures aims to bring talented people together in networks to prove out their ideas and solve hard problems in science and society.

Dr. Mary Maxon, Executive Director of the Schmidt Futures BioFutures Pprogram, remarked that "BioBuilder's accessible curriculum has made a substantial impact on secondary and post-secondary life-science education. We look forward to the plan they develop for scaling their early successes and expanding the geographic diversity of biotechnology opportunities."

For more information about The BioBuilder Education Foundation, please contact [info@biobuilder.org] or visit https://biobuilder.org.

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education - at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About Schmidt Futures:

Schmidt Futures bets early on exceptional people making the world better. Founded by Eric and Wendy Schmidt, Schmidt Futures is a philanthropic initiative that brings talented people together in networks to prove out their ideas and solve hard problems in science and society. To learn more about our method and the diverse types of capital and tools that we deploy, visit: https://www.schmidtfutures.com

Related link: https://biobuilder.org/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Alliances and Partnerships, Business, Education and Schools, Free News Articles, Sciences

BioBuilder and K2 Scientific Bring Synthetic Biology Programs and Laboratory Equipment to High-Need High Schools Around the Country

BOSTON, Mass. -- As a world-recognized program that trains the next generation of innovators and skilled workers in synthetic biology, the BioBuilder Educational Foundation announced new work with K2 Scientific to make high quality tools and equipment for life science research widely accessible. BioBuilder has partnered with K2 Scientific, who will donate industry-grade refrigeration units to four high-need high schools participating in the BioBuilderClub this academic year.

Consistent refrigeration of laboratory reagents is essential for a wide variety of biotechnology experiments and applications. Without precise temperature control and storage, materials and supplies for life science research degrade. Yet many high school educators, especially those in under-resourced school districts, rely on limited and unreliable cold-storage units. Many teachers forgo hands-on laboratory experiments without the appropriate cold storage equipment.

Recognizing that many high schools face financial constraints that limit classroom opportunities in the field of synthetic biology, BioBuilder annually runs the BioBuilderClub program. Since its inception in 2015, more than 1850 students from demographically and geographically diverse schools in 24 states and 7 countries have participated in a total of 202 BioBuilderClubs at low or no cost to the schools themselves. The BioBuilderClub supports real and meaningful student research, enabling high school students to take their ideas from concept to prototype to publication.

On November 9, 2022, staff and leadership from K2 Scientific and BioBuilder identified the first of four BioBuilderClubs to receive a freezer this academic year. The first recipient is the BioBuilderClub team from the Manhattan Comprehensive Night and Day High School (MCNDHS), a public school in New York City that serves students in grades 10-12.

Alfred Lwin, the MCNDHS BioBuilderClub lead teacher, said, "Our refrigerator is 20 years old, and sometimes we have difficulties using its freezer for cold storage. Thanks to the generous donation of a lab grade refrigerator by K2 Scientific, we will be able to use cold storage for our BioBuilder and other biotechnology labs."

Dee Jetton, COO from K2 Scientific, shared, "We could not be prouder to support this program. I am always so excited to see the great things the BioBuilder Program and its participants are accomplishing. We are thrilled to contribute to BioBuilder programs around the country. K2 Scientific is committed to equity and inclusion, so bringing medical and laboratory grade equipment to high-need schools is a perfect mission fit. It's nice for our team to learn about students' aha moments and accomplishments resulting from K2's support of young scientists in the field."

Founder and Executive Director of BioBuilder, Dr. Natalie Kuldell noted, "Our BioBuilderClubs are often the first - and sometimes the only - time high school students can engage in authentic research before they launch into college or careers. By making that research experience more accessible and more meaningful, we can effectively engage the next generation of scientific innovators and productively prepare our future citizens."

About BioBuilder:

Created by an award-winning team from MIT, BioBuilder empowers teachers and schools to better serve students and employers by elevating the skills that students are taught. Founded in 2011, BioBuilder has grown to partner with schools in almost every state and around the world. BioBuilder builds confidence in teachers to learn and apply the synthetic biology curricula, and provides laboratory kits and an openly accessible textbook that enable experiential learning.

BioBuilder also works directly with district and community leaders to identify potential roadblocks to narrow the gap between science innovation and science education - at least for biology - across the U.S., and better match the skill of our nation's workforce to the needs of the synthetic biology industry. Learn more by visiting https://biobuilder.org/.

About K2 Scientific:

K2 Scientific provides high-performance, medical, cold storage solutions at value prices, offering an extensive line serving US Life Science corporations and North and South American distributors. All K2 orders ship from the North Carolina basecamp. For more information, visit https://k2sci.com and follow us on LinkedIn, Instagram @K2_Scientific

Related link: https://biobuilder.org/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022

Alliances and Partnerships, Business, Free News Articles, Software

Dosaggio™ by SottoPelle® Partners with PatientNow

SCOTTSDALE, Ariz. -- Dosaggio™ by SottoPelle® and PatientNow announced today that they have entered into a partnership that integrates the two companies' innovative technologies, to improve efficiencies and elevate patient care for providers offering bioidentical hormone replacement therapy (BHRT).

This collaboration offers medical providers a powerful and seamless integration of capabilities for bioidentical hormone replacement therapy practices.

This partnership brings together PatientNow's robust functional EHR with the advanced and powerful Dosaggio™ hormone dosing tool, enabling medical providers to expand their functional medicine practices into the bioidentical hormone therapy arena.

PatientNow is a functional, full-service EHR that offers customized and integrated scheduling, charting, billing, reporting, prescription management, and treatment plan solutions for medical practices. The PatientNow EHR offers flexibility for each provider's needs - all with fair pricing.

The Dosaggio™ bioidentical hormone pellet therapy dosing application allows medical providers to optimize their patient's hormone health through precise, individualized hormone dosing. Dosaggio™ by SottoPelle® offers providers a proprietary online hormone dosing calculator that uses the patient's unique health data to calculate a precise, individualized BHRT dose. Dosaggio™ combines a powerful algorithm with on-screen clinical guidance that enables medical providers to approach each patient's hormone health care in an individualized manner.

The integration of these two platforms allows medical providers to pull patient data such as lab work, demographics, past hormone therapy notes, and other documentation from their PatientNow EHR into the Dosaggio™ dosing application. This eliminates the need for double documentation and helps seamlessly maintain continuity of care for BHRT patients.

"The Dosaggio and PatientNow integration will help providers bring quality care to their patients who suffer from hormonal imbalance," stated CarolAnn Tutera, CEO of Dosaggio™ by SottoPelle®. "It is our mission to help providers bring individualized care to more patients, to help them age gracefully."

Practices that are currently using PatientNow's EHR can conveniently set up their Dosaggio™ account by visiting the integrations page within their account. Medical providers who are interested in learning more about this exciting integration may visit: https://sottopelle.health.

Related link: https://www.sottopelletherapy.com/

This news story was published by the Neotrope® News Network - all rights reserved. ID:NEO2022